Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias Findings underscore potential to address unmet needs in multiple hematological malignancies, manufacturing innovation and …